TWI620737B - 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物 - Google Patents

作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物 Download PDF

Info

Publication number
TWI620737B
TWI620737B TW102140570A TW102140570A TWI620737B TW I620737 B TWI620737 B TW I620737B TW 102140570 A TW102140570 A TW 102140570A TW 102140570 A TW102140570 A TW 102140570A TW I620737 B TWI620737 B TW I620737B
Authority
TW
Taiwan
Prior art keywords
substituted
mmol
alkyl
occurrence
reaction
Prior art date
Application number
TW102140570A
Other languages
English (en)
Chinese (zh)
Other versions
TW201422587A (zh
Inventor
雷恩Ｍ 莫斯林
Ryan M. MOSLIN
藺恕群
Shuqun Lin
大衛Ｓ 文斯坦
David S. Weinstein
史蒂芬Ｔ 羅伯斯基
Stephen T. Wrobleski
張燕蕾
Yanlei Zhang
約翰Ｓ 托加斯基
John S. Tokarski
Original Assignee
必治妥美雅史谷比公司
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 必治妥美雅史谷比公司, Bristol-Myers Squibb Company filed Critical 必治妥美雅史谷比公司
Publication of TW201422587A publication Critical patent/TW201422587A/zh
Application granted granted Critical
Publication of TWI620737B publication Critical patent/TWI620737B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Dermatology (AREA)
TW102140570A 2012-11-08 2013-11-07 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物 TWI620737B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261723854P 2012-11-08 2012-11-08
US61/723,854 2012-11-08

Publications (2)

Publication Number Publication Date
TW201422587A TW201422587A (zh) 2014-06-16
TWI620737B true TWI620737B (zh) 2018-04-11

Family

ID=49667568

Family Applications (1)

Application Number Title Priority Date Filing Date
TW102140570A TWI620737B (zh) 2012-11-08 2013-11-07 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物

Country Status (15)

Country Link
US (1) US9315494B2 (cg-RX-API-DMAC7.html)
EP (1) EP2922841B8 (cg-RX-API-DMAC7.html)
JP (1) JP6259463B2 (cg-RX-API-DMAC7.html)
KR (1) KR102233252B1 (cg-RX-API-DMAC7.html)
CN (1) CN104781252B (cg-RX-API-DMAC7.html)
AR (1) AR093403A1 (cg-RX-API-DMAC7.html)
AU (1) AU2013341185B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015010244A8 (cg-RX-API-DMAC7.html)
CA (1) CA2890929A1 (cg-RX-API-DMAC7.html)
EA (1) EA028526B1 (cg-RX-API-DMAC7.html)
IL (1) IL238554A0 (cg-RX-API-DMAC7.html)
MX (1) MX2015005272A (cg-RX-API-DMAC7.html)
SG (1) SG11201503396UA (cg-RX-API-DMAC7.html)
TW (1) TWI620737B (cg-RX-API-DMAC7.html)
WO (1) WO2014074660A1 (cg-RX-API-DMAC7.html)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA028052B1 (ru) 2012-11-08 2017-10-31 Бристол-Майерс Сквибб Компани АЛКИЛАМИДЗАМЕЩЁННЫЕ ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ, ПРИГОДНЫЕ ДЛЯ МОДУЛЯЦИИ IL-12, IL-23 И/ИЛИ IFNα
CA2890983A1 (en) 2012-11-08 2014-05-15 Bristol-Myers Squibb Company Heteroaryl substituted pyridyl compounds useful as kinase modulators
PE20150944A1 (es) 2012-11-08 2015-06-20 Bristol Myers Squibb Co COMPUESTOS HETEROCICLICOS SUSTITUIDOS CON AMIDA UTILES COMO MODULADORES DE LAS RESPUESTAS DE INTERLEUCINA 12(IL-12), INTERLEUCINA 23 (IL-23) Y/O INTERFERON ALFA (IFN(alfa))
AR094537A1 (es) 2013-11-07 2015-08-12 Bristol Myers Squibb Co COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa
JP6458038B2 (ja) 2013-12-10 2019-01-23 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ＩＬ−１２、ＩＬ−２３および／またはＩＦＮα応答のモジュレーターとして有用なイミダゾピリダジン化合物
UY35935A (es) 2014-01-03 2015-06-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Compuestos de nicotinamida sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4
WO2016001341A1 (en) * 2014-07-03 2016-01-07 F. Hoffmann-La Roche Ag Sulfonylaminopyridine compounds, compositions and methods of use
WO2016022626A1 (en) * 2014-08-06 2016-02-11 Merck Sharp & Dohme Corp. Heterocyclic cgrp receptor antagonists
EP3313840B1 (en) 2015-06-24 2019-07-24 Bristol-Myers Squibb Company Heteroaryl substituted aminopyridine compounds
ES2822956T3 (es) 2015-06-24 2021-05-05 Bristol Myers Squibb Co Compuestos de aminopiridina sustituidos con heteroarilo
KR102641263B1 (ko) 2015-06-24 2024-02-26 브리스톨-마이어스 스큅 컴퍼니 헤테로아릴 치환된 아미노피리딘 화합물
CU24506B1 (es) 2015-11-26 2021-04-07 Novartis Ag Derivados de diamino piridina útiles paea tratar enfermedades susceptibles a la modulación de jak
JP7082130B2 (ja) 2016-10-14 2022-06-07 ニンバス ラクシュミ， インコーポレイテッド Ｔｙｋ２阻害剤およびその使用
EP3528816A4 (en) 2016-10-21 2020-04-08 Nimbus Lakshmi, Inc. TYK2 INHIBITORS AND USES THEREOF
JP7046092B2 (ja) * 2016-12-13 2022-04-01 ブリストル－マイヤーズ スクイブ カンパニー Ｉｌ－１２、ｉｌ－２３および／またはｉｆｎアルファ応答の調節剤としてのホスフィンオキシドアルキルアミド置換ヘテロアリール化合物
US10336752B2 (en) 2017-03-08 2019-07-02 Nimbus Lakshmi, Inc. TYK2 inhibitors, uses, and methods for production thereof
AU2018265130B2 (en) 2017-05-11 2022-03-24 Bristol-Myers Squibb Company Thienopyridines and benzothiophenes useful as IRAK4 inhibitors
TWI776810B (zh) * 2017-05-12 2022-09-11 瑞士商諾華公司 新穎二胺基吡啶衍生物
WO2019023468A1 (en) 2017-07-28 2019-01-31 Nimbus Lakshmi, Inc. TYK2 INHIBITORS AND USES THEREOF
KR102702228B1 (ko) * 2017-11-21 2024-09-02 브리스톨-마이어스 스큅 컴퍼니 술폰 피리딘 알킬 아미드-치환된 헤테로아릴 화합물
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
EP3752142A4 (en) 2018-02-13 2021-09-08 Rutgers, The State University of New Jersey ANTIBACTERIAL AGENTS: SOLUBLE SALTS AND AQUEOUS FORMULATIONS OF PYRONINS
US11685723B2 (en) 2018-02-13 2023-06-27 Rutgers, The State University Of New Jersey Antibacterial agents: O-alkyl-deuterated pyronins
US11572337B2 (en) 2018-03-06 2023-02-07 Rutgers, The State University Of New Jersey Antibacterial agents: arylalkylcarboxamido phloroglucinols
UY38144A (es) 2018-03-12 2019-10-31 Abbvie Inc Inhibidores de la señalización mediada por tirosina cinasa
EP3768667B1 (en) * 2018-03-22 2023-04-12 Bristol-Myers Squibb Company Heterocyclic compounds comprising pyridine useful as modulators of il-12, il-23 and/or ifn alpha responses
EP3817822A4 (en) 2018-07-06 2022-07-27 Kymera Therapeutics, Inc. PROTEIN DEGRADANTS AND USES THEREOF
AU2019360941B2 (en) 2018-10-15 2025-02-27 Takeda Pharmaceutical Company Limited TYK2 inhibitors and uses thereof
EA202191142A1 (ru) * 2018-10-30 2021-07-20 Бристол-Маерс Сквибб Компани Амидзамещенные гетероциклические соединения
JP7530360B2 (ja) 2018-11-30 2024-08-07 武田薬品工業株式会社 Ｔｙｋ２阻害剤およびその使用
KR20250167680A (ko) 2018-11-30 2025-12-01 카이메라 쎄라퓨틱스 인코포레이티드 Irak 분해제 및 이의 용도
CN113348021B (zh) 2019-01-23 2025-07-11 武田药品工业株式会社 Tyk2抑制剂和其用途
KR20210119426A (ko) * 2019-01-28 2021-10-05 장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 피리다진 유도체 억제제, 및 그의 제조 방법 및 용도
ES2960521T3 (es) 2019-07-18 2024-03-05 Bristol Myers Squibb Co Compuestos de pirazolo[3,4-D]pirrolo[1,2-B]piridazinilo útiles como inhibidores de IRAK4
EP3999508B1 (en) 2019-07-18 2023-08-30 Bristol-Myers Squibb Company Tricyclic heteroaryl compounds useful as irak4 inhibitors
WO2021016289A1 (en) 2019-07-23 2021-01-28 Bristol-Myers Squibb Company Thienopyridinyl and thiazolopyridinyl compounds useful as irak4 inhibitors
WO2021026181A1 (en) 2019-08-06 2021-02-11 Bristol-Myers Squibb Company Bicyclic heterocyclic compounds useful as irak4 inhibitors
JP2022547719A (ja) 2019-09-13 2022-11-15 ニンバス サターン， インコーポレイテッド Ｈｐｋ１アンタゴニストおよびその使用
US12391702B2 (en) 2020-02-03 2025-08-19 Bristol-Myers Squibb Company Benzo[5,6][1,4]dioxino[2,3-b]pyridine compounds useful as IRAK4 inhibitors
CN115335380B (zh) 2020-02-03 2024-08-02 百时美施贵宝公司 可用作irak4抑制剂的三环杂芳基化合物
US20220330549A1 (en) * 2020-03-11 2022-10-20 Northwest A&F University Use of n-benzylbenzamide-based compound as herbicide
KR20230004612A (ko) * 2020-04-14 2023-01-06 고사머 바이오 서비시즈 인코포레이티드 염증성 질병의 치료를 위한 치환된 피리딘
KR20230004771A (ko) 2020-04-28 2023-01-06 브리스톨-마이어스 스큅 컴퍼니 Il-12, il-23 및/또는 ifn알파 조정제로서의 치환된 n-(메틸-d3)피리다진-3-카르복스아미드 또는 n-(메틸-d3)-니코틴아미드 화합물
JP7537002B2 (ja) * 2020-08-07 2024-08-20 南京薬石科技股▲フン▼有限公司 Ｃｄｋ９阻害剤およびその使用
CN114181257B (zh) * 2020-09-14 2025-02-14 四川科伦博泰生物医药股份有限公司 吡啶类化合物，包含其的药物组合物，其制备方法及其用途
JP2023546996A (ja) 2020-10-23 2023-11-08 ニンバス クロソー， インコーポレイテッド Ｃｔｐｓ１阻害剤およびその使用
US20240076285A1 (en) * 2020-12-16 2024-03-07 Shankar Venkatraman Compounds and compositions for treating conditions associated with sting activity
JP2024503300A (ja) 2020-12-30 2024-01-25 カイメラ セラピューティクス， インコーポレイテッド Ｉｒａｋ分解剤およびそれらの使用
MX2023009059A (es) 2021-02-02 2023-09-15 Liminal Biosciences Ltd Antagonistas de gpr84 y usos de estos.
CN117098757A (zh) 2021-02-02 2023-11-21 里米诺生物科学有限公司 Gpr84拮抗剂和其用途
WO2022174253A1 (en) 2021-02-12 2022-08-18 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
TW202245788A (zh) 2021-02-15 2022-12-01 美商凱麥拉醫療公司 Irak4降解劑及其用途
WO2022175745A1 (en) * 2021-02-19 2022-08-25 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
KR20230159420A (ko) * 2021-02-19 2023-11-21 수도 바이오사이언시즈 리미티드 Tyk2 억제제 및 이의 용도
EP4294807A1 (en) * 2021-02-19 2023-12-27 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
AU2022222470A1 (en) 2021-02-19 2023-09-21 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
WO2022187856A1 (en) 2021-03-05 2022-09-09 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
US12071442B2 (en) 2021-03-29 2024-08-27 Nimbus Saturn, Inc. Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists
CA3214952A1 (en) 2021-04-09 2022-10-13 Silvana Marcel LEIT DE MORADEI Cbl-b modulators and uses thereof
KR20240111312A (ko) 2021-10-25 2024-07-16 카이메라 쎄라퓨틱스 인코포레이티드 Tyk2 분해제 및 이의 용도
AU2022378630A1 (en) 2021-10-29 2024-05-09 Kymera Therapeutics, Inc. Irak4 degraders and synthesis thereof
CN118401516A (zh) * 2021-12-16 2024-07-26 凌科药业(杭州)有限公司 Tyk2抑制剂及其组合物和方法
WO2023108536A1 (en) * 2021-12-16 2023-06-22 Lynk Pharmaceuticals Co. Ltd. Tyk2 inhibitors and compositions and methods thereof
JP2025504059A (ja) 2022-01-31 2025-02-06 カイメラ セラピューティクス， インコーポレイテッド Ｉｒａｋデグレーダー及びその使用
CN116693449A (zh) * 2022-03-04 2023-09-05 上海致根医药科技有限公司 用作tyk2抑制剂的化合物、其制备方法及其在医药上的应用
CN119585250A (zh) * 2022-04-19 2025-03-07 蓝图药品公司 Kit抑制剂
EP4532485A1 (en) * 2022-05-27 2025-04-09 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
KR20250057800A (ko) 2022-08-02 2025-04-29 리미널 바이오사이언시스 리미티드 헤테로아릴 카복스아마이드 및 관련 gpr84 길항제 및 이의 용도
WO2024028364A1 (en) 2022-08-02 2024-02-08 Liminal Biosciences Limited Aryl-triazolyl and related gpr84 antagonists and uses thereof
IL318576A (en) 2022-08-02 2025-03-01 Liminal Biosciences Ltd Pyridoxine-substituted GPR84 antagonists and their uses
WO2024249855A1 (en) * 2023-06-02 2024-12-05 Idrx, Inc. Combination therapy comprising kit inhibitors for use in the treatment of cancer
TW202529769A (zh) 2023-09-21 2025-08-01 日商武田藥品工業股份有限公司 Ｔｙｋ２抑制劑及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110230467A1 (en) * 2008-11-21 2011-09-22 Astellas Pharma Inc. 4,6-diaminonicotinamide compound
WO2012062704A1 (en) * 2010-11-09 2012-05-18 Cellzome Limited Pyridine compounds and aza analogues thereof as tyk2 inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176214B2 (en) 2003-05-21 2007-02-13 Bristol-Myers Squibb Company Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
GB0719644D0 (en) * 2007-10-05 2007-11-14 Cancer Rec Tech Ltd Therapeutic compounds and their use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110230467A1 (en) * 2008-11-21 2011-09-22 Astellas Pharma Inc. 4,6-diaminonicotinamide compound
WO2012062704A1 (en) * 2010-11-09 2012-05-18 Cellzome Limited Pyridine compounds and aza analogues thereof as tyk2 inhibitors

Also Published As

Publication number Publication date
EA201590913A1 (ru) 2015-10-30
EP2922841B1 (en) 2017-06-07
IL238554A0 (en) 2015-06-30
CN104781252B (zh) 2017-11-17
EP2922841B8 (en) 2017-08-02
BR112015010244A2 (pt) 2017-07-11
CN104781252A (zh) 2015-07-15
JP6259463B2 (ja) 2018-01-10
US20150307483A1 (en) 2015-10-29
AU2013341185B2 (en) 2017-07-13
BR112015010244A8 (pt) 2019-10-01
US9315494B2 (en) 2016-04-19
CA2890929A1 (en) 2014-05-15
AU2013341185A1 (en) 2015-07-02
MX2015005272A (es) 2015-07-14
TW201422587A (zh) 2014-06-16
JP2016506368A (ja) 2016-03-03
KR20150081338A (ko) 2015-07-13
AR093403A1 (es) 2015-06-03
KR102233252B1 (ko) 2021-03-26
SG11201503396UA (en) 2015-05-28
WO2014074660A1 (en) 2014-05-15
EP2922841A1 (en) 2015-09-30
EA028526B1 (ru) 2017-11-30

Similar Documents

Publication Publication Date Title
TWI620737B (zh) 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物
TWI582077B (zh) 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物
US11021475B2 (en) Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses
CN105992768B (zh) 用作IL‑12、IL‑23和/或IFNα响应的调节剂的咪唑并哒嗪化合物
KR102531036B1 (ko) Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 이미다조피리다진 화합물
HK1226400B (en) Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifnalpha responses

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees